Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IVVD - Invivyd Inc


IEX Last Trade
0.8601
-0.024   -2.732%

Share volume: 782,687
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.88
-0.02
-2.66%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-15.82%
1 Month
-28.55%
3 Months
-53.03%
6 Months
-79.61%
1 Year
-53.79%
2 Year
-81.02%
Key data
Stock price
$0.86
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.84 - $5.20
52 WEEK CHANGE
-$0.54
MARKET CAP 
101.550 M
YIELD 
N/A
SHARES OUTSTANDING 
119.443 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.74
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,040,216
AVERAGE 30 VOLUME 
$564,299
Company detail
CEO:
Region: US
Website: adagiotx.com
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.

Recent news